Table 2.

The associations (crude and adjusted OR and 95% CI) of migraine diagnosis and medication with stroke sub types

Migraine measures	Ischemic and unspecified stroke* (n=132,014)		Hemorrhagic stroke (n=14,299)		Transient ischemic attacks (n=8359)
	Crude OR 95% CI	Adjusted OR 95% CI	Crude OR 95% CI	Adjusted OR 95% CI	Crude OR 95% CI	Adjusted OR 95% CI
Migraine diagnosis	<50 y 5.27 (3.95–7.13); ≥50 y 1.87 (1.61–2.19)	<50 y 4.59 (3.42–6.15); ≥50 y 1.68 (1.48–2.05)	1.89 (1.27–2.84)	1.91 (1.29–2.83)	3.00 (1.95–4.73)	2.90 (1.89–4.44)
Migraine with aura	<50 y 4.02 (2.37–7.39); ≥50 y 2.04 (1.45–2.90)	<50 y 1.98 (1.51–2.60); ≥50 y 1.40 (1.18–1.65)	1.24 (0.50–3.10)	1.15 (0.75–1.75)	12.03 (3.00–104.89)	3.44 (1.67–7.10)
Migraine without aura or unspecified	<50 y 5.71 (4.06–8.22); ≥50 y 1.83 (1.54–2.18)	<50 y 4.86 (3.43–6.87); ≥50 y 1.66 (1.40–1.97)	2.10 (1.34–3.36)	1.91 (1.29–2.83)	2.32 (1.46–3.78)	2.22 (1.40–3.51)
Primary migraine medication	1.14 (1.08–1.18)	1.12 (1.06–1.17)	1.09 (0.96–1.24)	1.08 (0.95–1.22)	1.47 (1.27–1.71)	1.38 (1.19–1.60)
Triptans	1.15 (1.09–1.21)	1.14 (1.08–1.11)	1.11 (0.97–1.30)	1.12 (0.96–1.30)	1.55 (1.31–1.83)	1.45 (1.22–1.72)
Ergotamine	1.08 (0.99–1.10)	1.05 (0.96–1.18)	1.03 (0.81–1.31)	0.99 (0.78–1.25)	1.18 (0.85–1.62)	1.11 (0.81–1.56)
Secondary migraine medication	1.28 (1.24–1.33)	1.12 (1.09–1.16)	1.33 (1.20–1.47)	1.12 (1.01–1.24)	1.15(1.01–1.62)	1.06 (0.92–1.21)

Notes: Adjusted for gender, age, education, diabetes, hypertension, alcohol related disorder, chronic obstructive pulmonary disease, depression, use of oral contraceptives, hormone replacement therapy, and antithrombotic medication (acetylsalicylic acid, clopidogrel, and warfarin) and statins prior to diagnosis;

^*the estimates for ischemic and unspecified stroke were very similar and two subtypes were collapsed.